|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|||||||||||
|
|
Publications
> Poster
15. Khalid Abu Ajaj, Ralph Graeser, Yeonyu Lee, Felix Kratz
‘‘Prodrug-mediated reversal of
multidrug resistance in breast cancer cells’’ AACR Annual Meeting 2012 Chicago, IL, USA, March 31–April 4, 2012, submitted 14. Teuta Opacak-Bernardi, Leslie
Robinson, Khalid Abu Ajaj, Felix Kratz, Drazen Raucher ‘‘In vitro evaluation of a thermally
targeted conjugate of a highly potent doxorubicin derivative’’ AACR Annual Meeting 2011 Orlando, Florida, USA, April 2–6, 2011 13. Khalid Abu Ajaj, Naser El-Abadla, Pia Welker, Samar Azab, Reiner
Zeisig, Iduna Fichtner, Felix Kratz ‘‘Biological evaluation of folate
prodrugs with a highly toxic derivative of doxorubicin’’ AACR Annual Meeting 2011 Orlando, Florida, USA, April 2–6, 2011 12. Khalid Abu
Ajaj, Cynthia Schaefer-Obodozie, Norbert Esser,
Felix Kratz ‘‘Development of macromolecular
prodrugs with proteasome inhibitors’’ 8th International Symposium on Polymer
Therapeutics: From Laboratory to Clinical
Practice 11. Bakheet Elsadek, Ralph Graeser, Norbert Esser, Khalid Abu Ajaj,
Tahia Saleem, Nagla El Melegy, Hafez Madkor,
Felix Kratz ‘‘Development of a
novel water-soluble prodrug of paclitaxel that is cleaved by prostate-specific antigen
(PSA): In vitro and in vivo evaluation’’ AACR Annual Meeting 2010 Washington DC, USA, April
17–21, 2010 10. Khalid Abu Ajaj,
Ralph Graeser, Felix Kratz
‘‘Development of a dual-acting
prodrug with doxorubicin and the P-glycoprotein inhibitor ONT-093 for circumventing
multidrug resistance’’ AACR Annual Meeting 2009 Denver, Colorado, USA,
April 18–22, 2009 9. Khalid Abu Ajaj,
Felix Kratz
‘‘Development of
prodrugs for combination chemotherapy’’ AACR Annual Meeting 2009 Denver, Colorado, USA,
April 18–22, 2009 8. Khalid Abu Ajaj,
Ralph Graeser, Iduna Fichtner, Felix Kratz
"In vitro and in vivo study of an albumin-binding prodrug of
doxorubicin that is cleaved by cathepsin B" AACR Annual Meeting 2009 Denver, Colorado, USA, April
18–22, 2009 7. Felix Kratz, Claudia Ryppa, Khalid Abu Ajaj
‘‘Development of ligand-based and dual acting prodrugs as the next generation
of albumin-binding prodrugs’’ 7th International Symposium on Polymer
Therapeutics: From Laboratory to Clinical
Practice 6. Khalid Abu Ajaj, Ralph Graeser, Christoph Schaechtele, Felix Kratz ‘‘Development of prodrugs for combination
chemotherapy’’ AACR Annual Meeting 2008 San Diego, CA, USA, April 12–16,
2008 5. Gisa. Gerold,
Hans-Jürgen Laws, Khalid Abu Ajaj, Michael Bienert, Arturo Zychlinsky, Juana L. de Diego ‘‘Toll-like receptor 2 dependent pattern recognition requires
vitronectin and beta3 integrin’’ Keystone Symposium: Innate Immunity:
Signaling Mechanisms 4. Khalid Abu Ajaj, Felix
Kratz
‘‘Development of new albumin-binding dual acting prodrugs to overcome
P-glycoprotein-mediated multidrug resistance’’ AACR Annual Meeting 2007 Los
Angeles, CA, USA, April 14–18, 2007 3. Gisa Gerold, Juana de Diego, Khalid Abu Ajaj, Michael Bienert, Arturo Zychlinsky ‘‘An acute phase serum protein
negatively regulates the interaction of bacterial lipoprotein with toll-like receptor 2’’ Keystone Symposium: Innate Immunity to
Pathogens 2.
Juana de Diego, Khalid Abu Ajaj, Gisa Gerold, Micael Bienert, Arturo Zychlinsky ‘‘An acute phase serum protein
negatively regulates the interaction of bacterial lipoprotein with toll-like receptor 2’’ EURESCO conferences: Spatial and Temporal
Dynamics of the Endomembrane System San Feliu de Guixols, Spain,
October 16–21, 2004 1. Khalid Abu Ajaj, Yang Guangbin,
Svetlana Zakharova, Peter Welzel ‘‘Synthesis of phosphonate analogues of
moenomycin A12’’ Biology of bacterial natural substance
producers Workshop, Berlin, Germany Technical University, Berlin,
|
|
||||||||||||||
|
terms and conditions | ÇÊÝÇÞíÉ ÇÓÊÎÏÇã ÇáãæÞÚ | rechtlicher Hinweis |
|
AbuAjaj.com©
2001-2010 last change 23.11.2011 |